Based on this YouTube video's total view count of 113K views and industry-standard rates, the estimated total earning is $79 - $227 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Pandemic Science, Vaccines soon with 113,344 views, 4,865 likes, and 3,319 comments. Experience the impact of this video content that has captured audience attention.

University of Oxford and AstraZeneca Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups (AZ, 31st August) https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html https://www.inverse.com/mind-body/3-coronavirus-vaccines-explained AZD1222 Based on a chimpanzee adenovirus US, $1.2 billion EU, ordered 400 m doses 1st deliveries October Can make 2 billion doses Millions already produced in India So far https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext N = 543 14 days after receiving the vaccine 91% to 100% produced neutralizing antibodies Anti-spike IgG These antibodies prevent viruses from infecting healthy cells Therefore, likely to protect against COVID-19 Local and systemic reactions No serious adverse events Phase 3, 28 June, Brazil Now Final testing stage in US Enrolment for phase 3 clinical trials opened 30,000 adults, aged 18 years or over Diverse racial, ethnic, and geographic groups Healthy or have stable underlying medical conditions Randomly assigned Saline control, or two doses of AZD1222, Four weeks apart Twice as many people will receive the vaccine than not Testing for efficacy and safety The immune responses of 3,000 evaluated in detail Other late-stage AZD1222 trials have already begun in South Africa, Brazil, India, United Kingdom Russia and Japan soon, 50,000 participants worldwide THE MODERNA VACCINE CANDIDATE, MRNA-1273 https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins So far One dose caused some to produce binding antibodies Two doses caused all to produce neutralizing antibodies August 11, US, an additional $1.5 billion Messenger RNA (mRNA) adenine, cytosine, uracil, guanine Translation in the cytoplasm Ribosomes Copy of part of the virus's genetic sequence Protected by a lipid nanoparticle Directs cells to make a protein that works as a drug or vaccine Now Phase 3 clinical trials began July 27 30,000 healthy adults 2 doses Test for safety If the vaccine can prevent symptomatic COVID-19 ? how long will antibodies last THE PFIZER/BIONTECH VACCINE CANDIDATE, BNT162B2 US / German US, $1.9 billion pre-order So far mRNA vaccine Generates antibodies virus-neutralizing antibodies Generates T cells Now Phase 3 clinical trials started July 27 30,000 health adults in the US Expected to expand to 120 sites globally. Two-dose regime Encodes an optimized SARS-CoV-2 full-length spike glycoprotein Which is the target of virus-neutralizing antibodies To seek regulatory approval October Up to 100 million doses by the end of October 2020 China and Russia Skipped phase 3 trials NYT https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.